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The majority of cancer nurses have to manage intravascular devices (IVDs) on a daily 
basis, thus placing nurses in the strongest position to generate and use best available 
evidence to inform this area of practice, and to ensure that patients are receiving the 
best care available. Our literature clearly reflects that cancer nurses are concerned 
about complications associated with IVDs (e.g. extravasation,1 intravascular device-
related bloodstream infection (IVD-BSI),2, 3 and thrombosis4). Although enormous 
attention is given to this area, a number of nursing practices are not sufficiently based 
on empirical evidence.5, 6 Nurses need to set goals and priorities for future research 
and investments. Priority areas for future research are suggested here for your 
consideration. 
 
Safety and other patient-centered outcomes 
Effectiveness IVD-related research should include, but not be limited to, reducing 
adverse effects associated with IVDs and infusion practices7 and improving patient 
experiences. For example, IVD-BSI is increasingly recognized as a nurse sensitive 
patient outcome.7 IVD-BSI is associated with increased mortality and increased 
hospital stays (up to 20 days) and treatment costs (approximately 
US$56,000/episode).8, 9 It is crucial for nurses to recognise that our practices impact 
this important outcome. Our recent meta-analysis reported that the routine use of 
chlorhexidine impregnated dressings on central venous access devices (CVADs) can 
prevent one IVD-BSI in every 62 patients.10 There are now a number of available 
effective strategies for preventing IVD-BSI.11 However, further evidence is still 
required to answer some important clinically relevant questions: what dressings are 
the most effective for preventing IVD-BSI?3 how often do the dressings require 
changing for preventing IVD-BSI?2 
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Future effectiveness research also needs to address patient-centered outcomes. For 
example, patients receiving chemotherapy could experience up to eight failed 
attempts of peripheral venous cannulations before being successfully cannulated so 
that they can receive their chemotherapy.6 In such cases, nurse-led interventions can 
be designed and tested to address issues that are unpleasant or important to patients. 
Future IVD research should focus on what appears to be important from the lens of 
the health professionals and of the patients and carers/families.12 
 
Efficiency and/or cost of care  
Nurses have the responsibility to examine the efficiency and costs of care. Are we 
spending resources in care that are not based on evidence? Can we spend less to 
achieve the same or better patient outcomes? For example, a finding from a large 
nurse-led randomised controlled trial involving 3283 hospitalised patients,13  was  that 
peripheral intravenous catheters can be removed as clinically indicated, rather than 
every 72-96 hours. There is no difference in the phlebitis rates between groups.13 The 
cost-saving implication of practice change is expected to be enormous, considering 
the costs associated with the devices and personnel involved.13  Another example is 
that recommendation in a clinical guideline that patients with a previous venous 
puncture proximal to the administration site should not receive chemotherapy for at 
least 24 hours to prevent extravasation.14, 15 However, this guideline is not based on 
evidence. Our recent prospective study6  followed 77 patients who had more than one 
venous puncture proximal to the chemotherapy administration site; findings indicated 
that the 24 hour delay of treatment is unnecessary in the majority of patients, and can 
reduce the efficiency of care capacity of the cancer center.  
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Advancing nursing roles 
Future research of IVD care should also focus on generating evidence that advances 
the nursing role in managing IVDs. For example, the emerging clinical role of nurse-
led CVAD placement is exciting. A recent Australian study of 760 vascular access 
device placements in three intensive care units reported that nurse-led CVAD 
insertion is safe with low complications, as compared with previously published 
data.16  These results  indicated that nurses who are formally trained and credentialed 
to insert CVADs can improve organizational efficiencies.16  
 
In summary, future IVD research should focus on effectiveness, efficiency of care, 
and advancing nursing roles. Some of the examples provided above are based on 
indirect evidence. Where indirect evidence is the best available evidence, guideline 
developers and nurse researchers should examine the evidence critically and carefully, 
to determine whether further replication studies are required with cancer patients and 
nurses. It is an exciting time for cancer nurses to fully demonstrate that we can indeed 
make a difference in patient care outcomes by generating and utilizing best evidence 
IVD care to patients. 
 
My very best,  
Raymond Javan Chan 
RN, BN, MAppSc(Research), PhD(c), FACN 
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